Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibikase Therapeutics (IKT) Common Equity (2020 - 2025)

Inhibikase Therapeutics (IKT) has disclosed Common Equity for 6 consecutive years, with $72.9 million as the latest value for Q3 2025.

  • On a quarterly basis, Common Equity rose 13839.08% to $72.9 million in Q3 2025 year-over-year; TTM through Sep 2025 was $72.9 million, a 13839.08% increase, with the full-year FY2024 number at $94.9 million, up 764.16% from a year prior.
  • Common Equity was $72.9 million for Q3 2025 at Inhibikase Therapeutics, down from $80.1 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $94.9 million in Q4 2024 to a low of -$530591.0 in Q3 2024.
  • A 5-year average of $34.8 million and a median of $25.3 million in 2023 define the central range for Common Equity.
  • Peak YoY movement for Common Equity: crashed 103.53% in 2024, then surged 13839.08% in 2025.
  • Inhibikase Therapeutics' Common Equity stood at $38.4 million in 2021, then crashed by 45.24% to $21.0 million in 2022, then crashed by 47.81% to $11.0 million in 2023, then soared by 764.16% to $94.9 million in 2024, then fell by 23.16% to $72.9 million in 2025.
  • Per Business Quant, the three most recent readings for IKT's Common Equity are $72.9 million (Q3 2025), $80.1 million (Q2 2025), and $85.7 million (Q1 2025).